These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 25850038)
1. IDO inhibitors move center stage in immuno-oncology. Sheridan C Nat Biotechnol; 2015 Apr; 33(4):321-2. PubMed ID: 25850038 [No Abstract] [Full Text] [Related]
2. Marrying immunotherapy with chemotherapy: why say IDO? Muller AJ; Prendergast GC Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276 [TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy. Yentz S; Smith D BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987 [TBL] [Abstract][Full Text] [Related]
5. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Brochez L; Chevolet I; Kruse V Eur J Cancer; 2017 May; 76():167-182. PubMed ID: 28324751 [TBL] [Abstract][Full Text] [Related]
6. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy. Brochez L; Kruse V; Schadendorf D; Muller AJ; Prendergast GC Front Immunol; 2021; 12():789473. PubMed ID: 34938297 [No Abstract] [Full Text] [Related]
7. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies. Selvan SR; Dowling JP; Kelly WK; Lin J Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538 [TBL] [Abstract][Full Text] [Related]
9. In silico discovery and therapeutic potential of IDO1 and TDO2 inhibitors. Jernigan FE; Sun L Future Med Chem; 2017 Aug; 9(12):1309-1311. PubMed ID: 28771034 [No Abstract] [Full Text] [Related]
10. Research progress of indoleamine 2,3-dioxygenase inhibitors. Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005 [TBL] [Abstract][Full Text] [Related]
12. What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy? Eleftheriadis T Front Immunol; 2018; 9():1879. PubMed ID: 30150994 [No Abstract] [Full Text] [Related]
13. ASCO Reveals Additional Promising Results With Immunotherapies. Brower V J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26424738 [No Abstract] [Full Text] [Related]
14. Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development. Zhu MMT; Dancsok AR; Nielsen TO Curr Oncol Rep; 2019 Jan; 21(1):2. PubMed ID: 30659394 [TBL] [Abstract][Full Text] [Related]
15. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Löb S; Königsrainer A; Rammensee HG; Opelz G; Terness P Nat Rev Cancer; 2009 Jun; 9(6):445-52. PubMed ID: 19461669 [TBL] [Abstract][Full Text] [Related]